FY2024 EPS Estimates for Neurogene Lowered by William Blair

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Stock analysts at William Blair decreased their FY2024 earnings estimates for shares of Neurogene in a research report issued to clients and investors on Tuesday, November 19th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($4.33) per share for the year, down from their prior estimate of ($4.31). William Blair has a "Outperform" rating on the stock. The consensus estimate for Neurogene's current full-year earnings is ($4.45) per share. William Blair also issued estimates for Neurogene's Q4 2024 earnings at ($1.04) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.11) EPS and FY2025 earnings at ($4.32) EPS.

Several other research analysts have also recently issued reports on the company. Robert W. Baird raised their target price on Neurogene from $54.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 12th. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of Neurogene in a research report on Tuesday. BMO Capital Markets decreased their price target on shares of Neurogene from $60.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday. Leerink Partners lifted their price target on shares of Neurogene from $45.00 to $72.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 12th. Finally, Stifel Nicolaus upped their price objective on Neurogene from $44.00 to $60.00 and gave the stock a "buy" rating in a research note on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $60.83.

Neurogene Stock Performance

NGNE stock opened at $15.33 on Thursday. Neurogene has a 1 year low of $12.49 and a 1 year high of $74.49. The stock's fifty day moving average price is $45.90 and its 200-day moving average price is $39.79.

Institutional Investors Weigh In On Neurogene

A number of institutional investors have recently added to or reduced their stakes in NGNE. FMR LLC lifted its position in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company's stock worth $30,706,000 after buying an additional 659,515 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company's stock valued at $25,831,000 after acquiring an additional 457,062 shares during the period. Jennison Associates LLC bought a new position in shares of Neurogene in the 3rd quarter worth $3,300,000. Integral Health Asset Management LLC purchased a new stake in shares of Neurogene during the 2nd quarter worth $2,547,000. Finally, RTW Investments LP grew its stake in Neurogene by 6.0% in the third quarter. RTW Investments LP now owns 1,135,256 shares of the company's stock valued at $47,635,000 after purchasing an additional 64,691 shares during the last quarter. 52.37% of the stock is owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.